Business context and reporting period
This filing is Immudyne, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2014—not a filing identified as LifeMD, Inc. Immudyne develops and sells yeast beta-glucan nutraceutical and cosmetic products. It said it had exited the lower-margin animal-feed market in 2013 and was focusing on healthcare professionals, distributors, and direct-to-consumer sales.
Key financial results
| Metric | Three months ended June 30, 2014 | Six months ended June 30, 2014 | Comparable 2013 period |
|---|---|---|---|
| Sales | $196,611 | $389,040 | $322,903 quarter; $553,161 six months |
| Gross profit / margin | $127,455 / 64.8% | $270,794 / 69.6% | $257,235 / 79.7% quarter; $418,398 / 75.6% six months |
| Operating loss | $75,377 | $253,015 | $20,154 quarter; $90,941 six months |
| Net loss | $71,505 | $212,444 | $15,854 quarter; $57,341 six months |
| Operating cash flow | Not separately presented | $23,091 | $(37,873) six months |
At June 30, 2014, cash was $61,147 (down from $155,056 at December 31, 2013), current assets were $229,932, and current liabilities were $265,824. Working capital was negative $35,892 and the current ratio was 0.9 to 1. Total assets were $302,167; total liabilities were $287,624; stockholders’ equity was $14,543. Officer/director notes payable were $23,200, due on demand at 5% interest. Six-month financing cash outflow was $17,000, reflecting note repayment. No separate capital expenditure total is clearly provided.
Changes versus prior period
- Second-quarter sales fell 39.1% year over year; six-month sales fell 29.7%. Management attributed the decline to weaker demand and failure to execute plans to generate new business.
- Gross margin declined in both periods, with management citing overhead costs against lower sales volume.
- Six-month net loss increased to $212,444 from $57,341, as lower sales and largely sustained operating expenses outweighed lower costs.
- Second-quarter operating expenses fell 26.9%, partly due to the chief marketing officer’s resignation and reduced marketing expense; six-month operating expenses rose 2.8%, including first-quarter marketing costs.
- Six-month operating cash flow was positive largely because the company collected $132,000 of legal-settlement proceeds in the first quarter; cash nevertheless fell by $93,909 over the period.
Outlook, risks, and unusual items
- Going concern and financing: The company reported an accumulated deficit of approximately $8.3 million and stated that substantial doubt existed about its ability to continue as a going concern. Management expected to need additional capital for 2014 through higher sales, equity issuance, debt, or advances from officers/directors; financing was not assured.
- Concentration: One customer generated 82% of second-quarter sales and 87% of six-month sales, and represented 99% of accounts receivable at June 30. Management said it did not foresee collection difficulty.
- Management plans and risks: Immudyne was pursuing new marketing opportunities and expected marketing and advertising costs to rise as it sought to increase sales. It cited capital access, intellectual-property protection, government regulation, and lack of experienced personnel as important risks. No quantified revenue or earnings guidance was provided.
- Related-party and contractual obligations: Accrued royalties were $115,000 under an 8% royalty arrangement; the president had a 60% interest in royalties and deferred payment until the company could pay. Approximately $38,000 of the royalty commitment remained. Future minimum plant lease payments totaled $80,859.
- Other items: The company recorded $7,877 of other income from writing off old accounts payable. It invested $100,000 in Adiuvo Investment S.A.; the investment was carried at no value at June 30. It also issued 100,000 shares valued at $28,000 for consulting services. A further $25,000 installment remained due under a patent-license settlement.
- Controls: Management concluded disclosure controls were ineffective, citing material weaknesses including inadequate segregation of duties, insufficient written accounting/reporting procedures, inadequate system access and disaster-recovery safeguards, and no written whistleblower policy. Remediation was planned, subject to available funds.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Immudyne, Inc., not LifeMD, Inc.
- Assess the company’s ability to secure financing and sustain operations given low cash, negative working capital, and the going-concern warning.
- Evaluate dependence on the principal customer and the collectability of its share of receivables.
- Review the status and terms of the proposed marketing opportunities, along with the effect of the marketing chief’s departure.
- Check the payment status of accrued royalties and officer/director notes, and the value or progress of the Adiuvo investment and options.
- Track remediation of the reported material weaknesses and any subsequent changes in controls or financing.